VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

Historical Holders from Q1 2014 to Q3 2025

Symbol
VRTX on Nasdaq
CUSIP
92532F100
Type / Class
Equity / Common Stock
Shares outstanding
257M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
231M
Holdings value
$90.5B
% of all portfolios
0.037%
Grand Portfolio weight change
-0.006%
Number of holders
1473
Number of buys
664
Number of sells
-750
Average Value change %
0%
Average buys %
+0.006%
Average sells %
-0.008%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Capital World Investors 11.2% $13.9B 28.7M Capital World Investors Dec 31, 2024
Capital Research Global Investors 5.7% $7.04B 14.5M Capital Research Global Investors Mar 31, 2025
FMR LLC 3.6% $4.46B 9.22M FMR LLC Dec 31, 2024

Institutional Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 231M $90.5B -$3.67B $391.64 1,473
2025 Q2 240M $107B +$1.82B $445.20 1,539
2025 Q1 236M $115B +$568M $484.82 1,590
2024 Q4 236M $95B +$1.45B $402.70 1,527
2024 Q3 231M $107B -$1.91B $465.08 1,530
2024 Q2 234M $110B +$1.79B $468.72 1,532
2024 Q1 230M $96.2B -$1.7B $418.01 1,473
2023 Q4 2.14M $869M +$30.4M $406.89 20
2023 Q3 231M $80.5B -$566M $347.74 1,252
2023 Q2 231M $81.3B -$1.53B $351.91 1,253
2023 Q1 236M $74.5B +$552M $315.07 1,175
2022 Q4 235M $67.9B -$18.5M $288.78 1,189
2022 Q3 235M $68.2B +$550M $289.54 1,091
2022 Q2 228M $64.3B +$527M $281.79 1,078
2022 Q1 216M $56.3B +$112M $260.97 1,029
2021 Q4 224M $49.1B -$339M $219.60 1,001
2021 Q3 228M $41.3B -$34.4M $181.39 907
2021 Q2 226M $45.4B +$456M $201.63 951
2021 Q1 235M $50.5B -$679M $214.89 970
2020 Q4 238M $56.1B -$995M $236.34 938
2020 Q3 242M $65.8B -$118M $272.12 918
2020 Q2 242M $70.3B -$404M $290.31 942
2020 Q1 243M $57.8B +$326M $237.95 832
2019 Q4 243M $53.3B -$520M $218.95 794
2019 Q3 246M $41.6B +$12.6M $169.42 690
2019 Q2 241M $44.2B +$1.52B $183.38 697
2019 Q1 244M $45B +$391M $183.95 718
2018 Q4 243M $40.3B +$323M $165.71 685
2018 Q3 234M $45.1B +$4.07M $192.74 681
2018 Q2 241M $41B +$446M $169.96 679
2018 Q1 240M $39.1B +$125M $162.98 668
2017 Q4 239M $35.8B +$293M $149.86 629
2017 Q3 238M $36.1B +$313M $152.04 601
2017 Q2 236M $30.4B +$9.59M $128.87 563
2017 Q1 236M $25.8B +$2.16B $109.35 505
2016 Q4 236M $17.4B -$343M $73.67 465
2016 Q3 241M $21B +$81.6M $87.21 474
2016 Q2 240M $20.6B +$256M $86.02 467
2016 Q1 234M $18.6B +$171M $79.49 481
2015 Q4 234M $29.5B -$14.6M $125.83 506
2015 Q3 231M $24.1B +$687M $104.14 480
2015 Q2 227M $28B -$368M $123.48 491
2015 Q1 233M $27.5B +$466M $117.97 468
2014 Q4 230M $27.3B -$519M $118.80 465
2014 Q3 233M $26.2B +$764M $112.31 421
2014 Q2 227M $21.5B +$285M $94.68 403
2014 Q1 223M $15.8B +$98.6M $70.72 387